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ABSTRACT
Purpose: In this work, a non-targeted approach was used to unravel 
changes in the plasma lipidome of PCOS patients. The aim is to offer new 
insights in PCOS patients strictly selected in order to avoid confounding 
factors such as dyslipemia, obesity, altered glucose/insulin metabolism, 
cardiovascular disease, or cancer.
Results: Multivariate statistics revealed a specific lipidomic signature 
for PCOS patients without associated pathologies. This signature implies 
changes, mainly by down-regulation, in glycerolipid, glycerophospholipid 
and sphingolipid metabolism suggesting an altered biosynthetic pathway 
of glycerophospholipids and cell signaling as second messengers in women 
with PCOS. 
Conclusions:  Our study confirms that a lipidomic approach discriminates 
a specific phenotype from PCOS women without associated pathologies from 
healthy controls.
Methods: In a cross-sectional pilot study, data were obtained from 34 
subjects, allocated to one of two groups: a) lean, healthy controls (n = 20), 
b) PCOS patients (n = 14) with diagnosis based on hyperandrogenaemia, 
oligo-anovulation and abnormal ovaries with small follicular cysts. A detailed 
biochemical characterization was made and lipidomic profiling was performed 
via an untargeted approach using LC-ESI-QTOF MS/MS.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is an endocrine-
metabolic disorder in women of reproductive age with a 
prevalence, in dependence on the study population, of 
5–20% [1–11]. The key basic features for its diagnosis are 
hyperandrogenism, chronic anovulation, and polycystic 
ovaries [12–18]. PCOS pathology is often associated with 
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obesity [19–24], insulin resistance [21, 23, 25, 26], type 
II diabetes [11, 27], cardiovascular disease, metabolic 
syndrome [28–34], and gynecological cancer [35–38]. 
Female infertility and pregnancy loss are additional 
consequences of this disorder. In addition, PCOS has been 
also related to an increased oxidative stress and leukocyte-
endothelium interactions, suggesting mitochondrial 
dysfunction and cardiovascular events under this condition 
[39, 40].
Although hyperandrogenism is one of the underlying 
key factors in this syndrome [15, 41, 42], likely as the 
result of a primary defect in steroidogenesis [21], the 
pathological conditions associated with PCOS complicate 
the understanding of the disease’s origin becoming a big 
challenge for both clinical and scientific communities.
The recent development of comprehensive omics 
approaches has provided an opportunity to address 
open questions about this disorder. Thus, genomics, 
transcriptomics, and proteomics approaches suggest 
the existence of altered pathways that affect protein 
folding, cytoskeleton, immune response, inflammation, 
iron metabolism, fibrinolysis and thrombosis, TGF-beta 
pathway, insulin signaling pathway, intracellular calcium 
metabolism, and oxidative stress, among others, which 
could play a role in the pathophysiology of PCOS [43, 44]. 
At present moment, however, no conclusive results have 
been obtained and thus, no mechanistic conclusions can be 
formulated.
More recently, metabolomics has offered a new 
perspective to study PCOS [44, 45], because it is closer 
to the actual phenotype than either both genomics/
transcriptomics or proteomics. This approach allows to 
identify in plasma/serum and urine samples metabolites 
involved mostly in carbohydrate, lipid, and amino acid 
metabolism, as well as steroid hormone metabolism, as 
potential biomarkers for different PCOS phenotypes 
[46–49] or PCOS patients with other pathologies 
associated  (e.g. overweight/obesity [48, 50] or insulin 
resistance or type 2 diabetes [51–55]). Interestingly, a 
recent and unique metabolomic study centered in follicular 
niche demonstrated that mitochondrial dysfunction of 
cumulus cells can be important in the pathogenesis of 
PCOS [56]. Later on, three studies specifically focused on 
the lipid metabolism have allowed to define a lipidomic 
profile in PCOS patients compared with control women at 
different stages of menstrual cycle [57], or suffering from 
obesity [58, 59].
In all these studies, however, the group of PCOS 
patients showed an important phenotypic heterogeneity, 
basically due to two factors: a) the variability in the 
diagnosis criteria, and b) the broad range of overlaid 
metabolic traits (dyslipemia, obesity, insulin resistance, 
cardiovascular disease). As pathophysiological 
mechanisms underlying the different PCOS phenotypes 
may differ from each other, these constraints can lead to 
differential metabolomic profiles not necessarily ascribed 
to the basic PCOS condition.
In this work, UPLC-QTOF-MS-based lipidomics 
approach was used to unravel changes in the plasma 
lipidome of PCOS patients. The aim of the study is to offer 
new insights in PCOS patients strictly selected in order 
to avoid confounding factors such as dyslipemia, obesity, 
altered glucose/insulin metabolism, cardiovascular 
disease, or cancer.
RESULTS
Clinical and metabolic characteristics
The clinical and metabolic characteristics of control 
and PCOS women are presented in Table 1. 
No statistically significant differences were 
found for age, BMI, waist, or blood pressure between 
PCOS and control women. Regarding the metabolic 
parameters, PCOS patients showed no changes in 
general lipid metabolism (total cholesterol, cholesterol-
LDL, cholesterol-LDL, or triacylglycerides), glucose 
metabolism (glucose, HBA1c, insulin, or HOMA), 
endocrine system (FSH, LH, androstendione, or SHBG), 
and inflammatory marker (hsCRP) with respect to control 
subjects. Higher total testosterone levels (p < 0.002) in 
PCOS women than in controls was the only biochemical 
parameters significantly different.
Plasma lipidomic signature of PCOS patients
The first goal of this study was to analyze global 
lipidomic differences between PCOS patients and healthy 
controls. Thus, we applied a non-targeted lipidomics 
approach focusing on the profiles of low molecular weight 
(m/z between 300 and 3000) ionizable lipid molecules. 
First, we detected 13380 features but after applied the 
MFE algorithm, 1320 features remained. Then, we filtered 
by frequency keeping those features present in at least 
50% of the samples of each group, so 339 lipid species 
integrate the studied lipidome.
First of all, we analyzed whether specific lipid 
species correlate with the most used plasma biomarker of 
PCOS pathogenesis, total plasma testosterone, and also the 
only clinical parameter studied which revealed statistically 
different levels between groups (Table 1). The results 
indicate that 72 compounds statistically correlated with 
testosterone levels (Supplementary Table 2), suggesting a 
relationship between androgenic endocrine regulation and 
these lipid species.
To determine whether the metabolite fingerprints 
in plasma differed between PCOS patients and healthy 
control subjects multivariate statistics were applied 
(Figure 1). Non-supervised PCA (Figure 1A) shows that 
there is an almost perfect clusterization of both groups 
suggesting a specific plasma lipidomic signature for PCOS 
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subject without associated pathologies comparing to 
healthy control individuals. These results were confirmed 
by a supervised method such as PLS-DA (Figure 1B) 
where the both groups are perfectly discriminated. 
Cross validation values of PLS-DA model (Figure 1C) 
confirm that it is a good model to discriminate between 
PCOS and controls obtaining an accuracy value up to 0.8 
and a maximum value of R2 using 3 components. The 
lower values of Q2 could be explained by the reduced 
number of individuals used in this study.  After building 
the PLS-DA model, variable importance in projection 
(VIP) score was applied to rank the distinctive features 
based on their significance in discriminating between 
groups. Lipid molecular species with VIP score > 2 were 
selected as significant variables. Figure 1D shows the key 
differentiating lipid species sorted by increasing VIP score. 
Taking a VIP cut-off at 2, 15 molecular species were found 
to be significant discriminators between groups. Among 
them, we could identify (basing on exact mass, retention 
time, isotopic distribution and/or MS/MS spectrum) two 
glycerophospholipids (the phosphatidylglyceride 33:0, PG 
(33:0); and the phosphatidic acid 41:2, PA(41:2)) and a 
sphingolipid, the ceramide t34:0 (Cert34:0), all of them 
decreased in PCOS patients. 
To better characterized plasma lipidomic signature 
of PCOS patients hierarchical clustering analyses using 
all 339 lipid species detected was performed (Figure 2A). 
This analysis reinforced the idea of a specific lipidomic 
signature of PCOS patients although a perfect separation 
is not reached.
After global characterization using multivariate 
statistics we wanted to describe changes in specific lipid 
species. To reach this goal, parametric T Test for unequal 
variances (p < 0.05, False Discovery Rate correction) 
was applied. Among 339 lipid species detected, 56 were 
statistically different between groups. 11 lipid species 
were identified (Table 2) and the remaining are still 
unidentified (Table 3).
Among the identified lipids we found 6 lipids 
belonging to glycerophospholipids family, two belonging to 
sphingolipids and three glycerolipids. When a hierarchical 
analysis to statistically significant molecules was applied, 
we did not obtain a better clusterization than using the 
whole lipidome (Figure 2B).
To further characterize the predictive value of 
these metabolites to discriminate PCOS condition, 
we performed ROC analyses using MS peak areas. 
Supplementary Table 3 shows the lipid species with an 
Table 1: Anthropometric and metabolic parameters in healthy control subjects and PCOS patients
 Controls (n = 20) PCOS  (n =14) P value
Age (years) 23.85 ± 5.63 24.14 ± 5.01 0.877
BMI (kg/m2) 20.78 ± 1.59 21.78 ± 2.77 0.362
Waist (cm) 76.50 ± 6.26 80.50 ± 9.41 0.127
Systolic BP (mmHg) 110.74 ± 14.46 112.93 ± 12.66 0.654
Diastolic BP (mmHg) 69.00 ± 10.81 71.50 ± 9.25 0.812
Total cholesterol (mg/dl) 163.00 ± 21.64 150.00 ± 33.22 0.494
LDLc (mg/dl) 85.00 ± 18.01 86.50 ± 24.59 0.528
HDLc (mg/dl) 61.00 ± 12.12 49.00 ± 9.52 0.051
Triglycerides (mg/dl) 63.15 ± 25.50 55.71 ± 21.40 0.379
Glucose (mg/dl) 82.50 ± 5.79 83.00 ± 8.79 0.806
Insulin (mg/dl) 5.65 ± 2.18 6.25 ± 1.99 0.969
HOMA-IR (mg/dl) 1.13 ± 0.45 1.25 ± 0.44 0.984
HbA1c (%) 5.08 ± 0.27 5.13 ± 0.25 0.783
FSH (mIU/ml) 3.90 ± 2.19 4.80 ± 1.44 0.054
LH (mIU/ml) 4.99 ± 4.90 5.72 ± 3.44 0.664
Total testosterone (ng/ml) 0.33 ± 0.12 0.53 ± 0.20 0.002
Androstendione (ng/ml) 3.35 ± 1.36 3.49 ± 1.37 0.506
SHBG (nmol/l) 81.05 ± 73.66 68.45 ± 31.83 0.455
hsCRP (mg/l) 1.12 ± 1.21 2.20 ± 2.34 0.103
Data are expressed as mean ± SD for parametric data and median (interquartile range) for non-parametric variables. 
Statistical significance (p < 0.05) was considered when compared by an unpaired Student’s t-test or Mann-Whitney U-test 
for parametric or non-parametric data, respectively. Adjustment of variables by BMI was carried out using a univariate 
general linear model. 
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area under the curve (AUC) higher to 0.8. Among them, 
the identified molecules with a higher AUC (PG (33:0), 
PA (41:2), DG (44:6) and PA (39:3)) had lower levels in 
PCOS individuals than in healthy controls (Figure 3). 
In addition with these changes, we also verified 
the existence of minor but significant differences in total 
plasma fatty acid profile between groups (Table 4). For 
particular fatty acids, there was a significant increase in the 
content of 14:0, and 24:0 in PCOS women; whereas 18:4n-
3, 20:0, 20:1n-9, 20:2n-6, 20:5n-3, 22:4n-6, 22:5n-3, 
24:1n-9, and 26:0 were decreased in PCOS group. These 
minor changes lead to a slight but significant change in 
the average chain length (ACL). Any additional change is 
verified for the other fatty acid indexes such as SFA, UFA, 
MUFA, PUFA, PUFAn-3, PUFAn-6, DBI, PI, or AI. 
DISCUSSION
Previous metabolomic studies using plasma, 
serum, urine and follicular fluids suggested marked 
metabolic shifts associated with PCOS disease. In these 
studies, metabolomics techniques have been applied in 
PCOS patients suffering from obesity, insulin resistance, 
cardiovascular disease or treated with polytherapy in order 
to refine their molecular traits [44, 45, 47, 49–55]. The 
results suggested some particular changes in lipid profile, 
and different levels of free fatty acids, phosphoglycerides, 
and sphingolipids are recurrent findings. It is important to 
be in mind that human diseases such as obesity, diabetes 
and cardiovascular disease are linked with disturbances 
in lipid metabolism and, consequently, it could be very 
difficult to discern whether PCOS per se also shows 
alterations in lipid metabolism when PCOS patients with 
associated pathologies are studied.
Further, previous studies focused in PCOS patients 
strictly diagnosed by the basic triad (polycystic ovaries, 
amenorrhea and hyperandrogenism) in absence of 
associated pathologies suggested minor changes in lipid 
metabolism. Only slightly increased LDL-cholesterol and 
decreased HDL-cholesterol, as well as total cholesterol, 
have been described [57–59]. In this line, in our study 
(only focused in PCOS patients without associated 
Figure 1: Multivariate statistics revealed the existence of a specific lipidomic signature of PCOS patients. Both unsupervised 
Principal Component Analyses (PCA) (A) and supervised Partial Least Discriminant Analyses (s-PLS-DA) (B) indicate that it is possible to 
discriminate between healthy controls and PCOS patients basing on their plasma lipidome. (C) Cross validation (CV) analyses (10-fold CV 
method) indicates that we obtained the maximum accuracy using only one component. (D) Among the metabolites which most contribute 
to define the first component of PLS-DA we could identify (basing on exact mass, retention time, isotopic distribution and/or MSMS 
spectrum) the phosphatidylglyceride 33:0 (PG330), the phosphatidic acid 41:2 (PA412) and the ceramide t34:0 (Cert34:0). Unknown 
identities are represented as exact mass_retention time.
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pathologies) we did not find changes in the levels of 
triglycerides, total cholesterol, LDLc and HDLc, glucose 
levels, hemoglobin A1c, insulin, and HOMA index. 
However, this apparent low impact of PCOS pathology 
in lipid metabolism could be masked by limitations in 
the biochemical analysis where very few lipid species are 
analyzed (basically, triacylglycerides and cholesterol). In 
contrast, mass spectrometry (MS) and nuclear magnetic 
resonance (NMR)-based techniques have become 
powerful tools for high-throughput screening for lipid 
characterization giving us the possibility to describe the 
complete lipid profile (lipidome) within an organism, 
organ, tissue, cell, organelle, subcellular membrane or 
microdomain, and biological fluids. In this scenario, the 
human plasma lipidome is composed of more than 3000 
confirmed lipid compounds which represent around 80% 
of the total human plasma metabolome [60].
In the present study we applied an LC-MS-
based technique in order to describe specific changes 
in plasma lipidome which could be only attributed 
to PCOS physiopathology. The results demonstrated 
for the first time the existence of a plasma lipidomic 
profiling specifically associated with PCOS patients. This 
signature could be defined by 15 molecules including 
two glycerophospholipids (PG (33:0), PA (41:2)) and a 
sphingolipid (Cer(t34:0). Unfortunately, the other species 
are still unidentified.
Further, we found 56 lipid molecular species with 
different concentration (4 lipid species were up-regulated 
(7.1%), whereas 52 were down-regulated (92.9%)) in 
plasma from PCOS patients compared to healthy controls. 
Among them, 11 (19.3%) were identified (based on exact 
mass, retention time, isotopic distribution, and/or MS/MS 
spectrum) and different functions can be attributed. 
The identified lipid species (11) belong to diverse 
lipid classes such as glycerolipids (5), glycerophospholipids 
(5), and sphingolipids (1), all of them down-regulated. 
One of the main components of cellular membranes are 
glycerophospholipids (GP), which are synthesized from 
glycerol-3-phosphate in a de novo pathway that primarily 
produces phosphatidic acid (PA) and diacylglycerol 
(DAG) or cytidine diphosphate-DAG (CDP-DAG). 
Via the de novo pathway, different types of GPs such as 
phosphatidylcholine (PC), phosphatidylethanolamine 
(PE), phosphatidylserine (PS), phosphatidylinositol (PI), 
phosphatidylglycerol (PG), and cardiolipin (CL) are 
generated. Subsequently, GP acyl chains are remodeled, 
via generation of lysoglycerophospholipids, by regulated 
and coordinated reactions of diverse enzymes [61]. Thus, 
the decreased content observed in PCOS patients of 
different lipid species such as PA (2), DAG (3), and even 
TAG (1), PG (2), PS(1), and LPE(1) suggest that PCOS 
is associated with a lower de novo biosynthesis pathway 
of glycerophospholipids and lower remodeling activity 
of PE likely due to the hyperandrogenism ascribed to 
PCOS. In addition, the decreased content in the identified 
ceramide (1) is probably also linked to a decreased de novo 
synthesis induced by PCOS status instead of an increase 
in degradation pathway. Globally, the down-regulation of 
the identified lipid species likely due to a decreased activity 
of the biosynthesis pathway along with the minor changes 
in the total plasma fatty acid composition could explain 
the not alterations o minor changes for LDL and HDL 
levels described in PCOS patients.  This particular lipid 
profile can also have additional effects derived from their 
role as lipid second messengers for some of them such as 
DAGs and ceramides. These molecules have been linked 
to obesity, insulin resistance, and metabolic disorders [62]. 
Table 2: Identified compounds statistically different between groups (T-test unpaired with Benjamini Hochberg 
correction false discovery rate)  




m/z Retention Time Product ion
Glycero-
phospholipids
LysoPE(20:4) 4.49E-04 4.83E-03 down 502.2839 0.86 M+H+
PA(39:3) 1.81E-04 2.27E-03 down 758.5633 7.63 M+NH4+
PA(41:2) 7.51E-07 5.09E-05 down 771.584 6.36 M+H+
PG(32:1) 1.03E-03 9.65E-03 down 721.5012 7.98 M+H+
PG(33:0) 3.71E-07 4.20E-05 down 754.5572 6.36 M+NH4+
PS(O-29:0) 5.17E-03 3.31E-02 down 680.4733 7.98 M+H+
Sphingolipids Cer(t34:0) 2.98E-06 9.57E-05 down 556.5276 8.29 M+H+
Glycerolipids
DG(44:6) 6.82E-05 1.16E-03 down 763.5499 8.96 M+K+
DG(33:2) 7.49E-05 1.21E-03 down 596.5205 8.3 M+NH4+
DG(32:3) 3.38E-04 3.82E-03 down 580.5062 5.87 M+NH4+
TG(43:1) 4.55E-04 4.83E-03 down 757.6426 9.18 M+Na+
Lipid species were identified by exact mass, retention time, isotopic distribution and MS/MS spectrum.
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Table 3: Unidentified compounds statistically different between groups (T-test unpaired with Benjamini Hochberg 
correction false discovery rate)  
Compounds p.value FDR Mass Retention Time PCOS vs Healthy 
Controls
674.6712_10.73 7.87E-08 1.44E-05 674.6712 10.74 down
1198.7675_7.3 8.52E-08 1.44E-05 1198.7675 7.31 down
890.2705_6.55 5.45E-07 4.62E-05 890.2705 6.56 up
306.3266_3.12 9.90E-07 5.60E-05 306.3266 3.12 down
625.7527_7.4 1.24E-06 6.00E-05 625.7527 7.41 down
576.5118_6.36 1.71E-06 7.27E-05 576.5118 6.36 down
631.5911_8.28 3.10E-06 9.57E-05 631.5911 8.29 down
567.6994_7.4 2.78E-06 9.57E-05 567.6994 7.41 down
698.5899_9.17 5.76E-06 1.50E-04 698.5899 9.17 down
1193.8123_7.3 5.75E-06 1.50E-04 1193.8123 7.31 down
1169.0583_8.27 1.35E-05 3.28E-04 1169.0583 8.27 down
856.8268_10.44 1.79E-05 3.90E-04 856.8268 10.44 down
347.3402_5.21 1.84E-05 3.90E-04 347.3402 5.21 down
699.6212_9.89 2.65E-05 5.28E-04 699.6212 9.9 down
897.8524_10.46 3.89E-05 7.32E-04 897.8524 10.46 down
504.3941_6.51 4.89E-05 8.73E-04 504.3941 6.51 down
625.7522_7.01 7.95E-05 1.22E-03 625.7522 7.02 down
590.5622_8.3 8.54E-05 1.26E-03 590.5622 8.3 down
782.2708_0.84 1.18E-04 1.57E-03 782.2708 0.85 down
446.3408_6.48 1.20E-04 1.57E-03 446.3408 6.48 down
1330.226_10.74 1.19E-04 1.57E-03 1330.226 10.75 down
166.027_6.39 2.19E-04 2.65E-03 166.027 6.39 down
375.1667_0.82 3.38E-04 3.82E-03 375.1667 0.82 down
1257.9644_8.21 6.29E-04 6.46E-03 1257.9644 8.21 down
665.6127_10.55 8.87E-04 8.84E-03 665.6127 10.56 down
565.6866_7.41 9.76E-04 9.45E-03 565.6866 7.42 down
1908.5245_10.59 1.26E-03 1.09E-02 1908.5245 10.59 down
1510.3676_10.49 1.23E-03 1.09E-02 1510.3676 10.5 down
1337.2762_10.76 1.20E-03 1.09E-02 1337.2762 10.77 down
707.4812_1.74 1.41E-03 1.20E-02 707.4812 1.75 down
148.0162_6.48 1.56E-03 1.27E-02 148.0162 6.48 down
1331.2296_10.76 1.58E-03 1.27E-02 1331.2296 10.76 up
1214.7404_7.26 1.84E-03 1.45E-02 1214.7404 7.27 down
1297.1666_10.77 2.46E-03 1.90E-02 1297.1666 10.77 down
849.2429_6.54 3.31E-03 2.49E-02 849.2429 6.55 up
795.539_7.54 3.62E-03 2.61E-02 795.539 7.55 down
1566.5088_10.07 3.55E-03 2.61E-02 1566.5088 10.07 down
1612.4489_10.36 4.08E-03 2.82E-02 1612.4489 10.36 down
1418.4786_9.88 4.06E-03 2.82E-02 1418.4786 9.88 down
944.8481_10.43 4.20E-03 2.85E-02 944.8481 10.43 down
1164.0236_8.29 4.51E-03 3.00E-02 1164.0236 8.29 down
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Consequently, the decrease in some of the DAGs may be a 
reason why these PCOS patients have not developed any 
of the metabolic diseases associated yet. According to our 
results, this pathway could be differentially regulated in 
PCOS patients and affected at long-term during the natural 
history of the disease and be involved in infertility and 
pregnancy loss, two main clinical consequences of this 
pathology [63, 64]. An interesting additional observation 
derived from our study is that free fatty acids (FFAs) are not 
differential lipid species between PCOS women and healthy 
control, in contrast to several previous metabolomics and 
lipidomics studies where systematic increases in free fatty 
acid contents are described [44, 45, 50, 51, 53, 54, 65]. FFAs 
are important for physiological homeostasis, providing 
a major portion of mammalian bioenergetics needs. In 
addition, FFAs are the substrate by which TAG stored in 
adipose tissue is transported to its sites of consumption, 
being the adipose tissue the only significant site of FFA 
release into plasma [66]. Therefore, the results of our study 
demonstrate that the described changes in lipid species can 
be ascribed specifically to the PCOS condition, whereas the 
described changes in FFAs in most studies are derived from 
the obesity associated to PCOS women. 
In conclusion, our study demonstrates that PCOS 
per se is a pathological entity that also presents alterations, 
though modest, in lipid metabolism. Although sample 
size is small, and should be validated in other cohorts, 
the accuracy in the elected group ensures and offers 
valuable information about the physiopathology of PCOS. 
Furthermore, our study confirms that using a lipidomic 
approach it is able to discriminate a specific phenotype 
from PCOS women without others associated pathologies.
MATERIALS AND METHODS
Subjects
The study was conducted in the Service of 
Endocrinology at the University Hospital Dr. Peset 
(Valencia, Spain). Fourteen women with PCOS and 
403.1982_0.85 5.05E-03 3.29E-02 403.1982 0.85 down
897.7787_10.02 6.20E-03 3.89E-02 897.7787 10.02 down
872.2602_8.96 7.76E-03 4.78E-02 872.2602 8.96 down
1328.2119_10.68 7.96E-03 4.82E-02 1328.2119 10.68 up
Unknown identities are represented as exact mass_retention time.
Figure 2: (A) Heat map representation of hierarchical clustering of 339 molecular features found in PCOS patients and healthy control 
plasma samples. (B) Heat map representations of hierarchical clustering analyses using 50 most statistical significant lipids species (T-test 
Unpaired with Benjamini Hochberg Correction) between PCOS and control samples. Unknown identities are represented as exact mass_
retention time. Each line of this graphic represents an accurate mass ordered by retention time, coloured by its abundance intensity 
normalized to internal standard and baselining to median/mean across the samples. The scale from -7 (blue) to 7 (red) represents this 
normalized abundance in arbitrary units.
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20 controls were selected according to age and body 
mass index (BMI). Table 1 shows anthropometric and 
metabolic parameters in control subjects and PCOS 
patients participating in this study. Controls were 
volunteers recruited from the University Hospital Dr 
Peset and the Faculty of Medicine (Valencia University, 
Valencia, Spain). PCOS subjects were diagnosed using 
the Rotterdam criteria [13], which are the following: 
oligoovulation (cycles longer than 35 days or less than 
26 days) [5]; elevated free testosterone levels (>0.5 ng/dl; 
the cut-off level for free testosterone was the mean ± 2 
SD according to normal levels in controls); hirsutism 
(total Ferriman-Gallwey score > 7) and polycystic 
ovaries (presence of 12 or more small -2 to 9 mm- 
follicles in each ovary), identified by trans-vaginal 
ultrasonography. Ultrasound scans were performed and 
scored independently by one of two experienced and 
blinded reviewers. None of the subjects had any systemic 
or endocrine disease or galactorrhea, or any condition 
affecting her reproductive physiology. Exclusion criteria 
were active infectious diseases, malignant neoplasia, 
diabetes mellitus, anemia, thromboembolism, history of 
ischaemic heart disease, stroke and the taking of lipid-
lowering or antihypertensive drugs. Absence during the 
previous semester of any medication that might have 
affected the hypothalamic-pituitary-gonadal axis was 
confirmed in all subjects. The study was approved by 
the ethics committee of the University Hospital Dr. Peset 
and was performed in accordance with the Helsinki 
declaration. Informed consent of all participants was 
obtained as required by these institutions.
Biochemical determinations
An anthropometric evaluation was performed in 
all subjects in whom weight (kg), height (m) and waist 
circumference (cm) were measured. Body mass index was 
then calculated (BMI = weight (kg)/height (m)2). After 12 
hours of fasting, blood was collected from the antecubital 
vein at 8–10 a.m, on the second/third day of the menstrual 
cycle (follicular phase) or after 3 months of amenorrhea. 
In subjects with very irregular cycles, blood was collected 
after progesterone deprivation. Samples were processed 
immediately in order to avoid haemolysis and were frozen 
until analysis.
Total cholesterol and triglycerides were measured 
using enzymatic assays. Concentration of low density 
lipoproteins cholesterol (LDLc) was calculated using 
the Friedewald formula, and high density lipoproteins 
cholesterol (HDLc) levels were recorded using a direct 
method with a Beckman LX-20 autoanalyser (Beckman 
Coulter, La Brea, CA, USA). The intraserial variation 
coefficient was <3.5 % for all determinations. An 
Automatic Glycohemoglobin Analyzer was employed to 
Figure 3: Receiver operating characteristic curve of (A) phosphatidylglicerol 33:0 (PG (33:0), (B) phosphatidic acid 41:2 (PA (41:2)), (C) 
diacylglycerol 44:6 (DG (44:6)) and (D) PA (39:3).
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assess HbA1c (Arkray, Inc., 73 KYOTO, Japan). Glucose 
levels were measured with a Dax-72 autoanalyzer using 
enzymatic techniques (Bayer Diagnostic, Tarrytown, NY, 
USA). Insulin concentration was determined by means of 
an enzymatic luminescence technique. High sensitivity 
C-reactive protein (hsCRP) levels were assessed by an 
immunonephelometric assay (Behring Nephelometer II, 
Dade Behring, Inc., Newark, DE, USA) with an intra-
assay coefficient of variation of 8.7% and sensitivity 
of 0.01 mg/L. IR was calculated by homeostasis model 
assessment (HOMA) using baseline glucose and insulin: 
HOMA = (fasting insulin (μU/ml) × fasting glucose 
(mmol/L)/22.5. Serum luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) were measured using a 
Table 4: Total fatty acid composition of plasma from control subjects and PCOS patients
Control PCOS P value
C14:0 0.401 ± 0.023 0.608 ± 0.054 0.001
C16:0 20.563 ± 0.469 21.553 ± 0.370 0.130
C16:1n-7 1.149 ± 0.093 1.351 ± 0.130 0.203
C18:0 7.967 ± 0.496 8.319 ± 0.128 0.559
C18:1n-9 20.615 ± 0.391 20.336 ± 0.628 0.694
C18:1n-7 1.797 ± 0.052 1.746 ± 0.046 0.514
C18:2n-6 32.502 ± 0.774 32.123 ± 1.033 0.767
C18:3n-3 0.309 ± 0.017 0.314 ± 0.036 0.881
C18:4n-3 0.205 ± 0.007 0.140 ± 0.006 0.001
C20:0 0.302 ± 0.013 0.160 ± 0.006 0.001
C20:1n-9 0.276 ± 0.013 0.232 ± 0.009 0.019
C20:2n-6 0.067 ± 0.009 0.041 ± 0.003 0.031
C20:3n-6 1.502 ± 0.080 1.405 ± 0.086 0.425
C20:4n-6 6.626 ± 0.300 6.534 ± 0.365 0.847
C20:5n-3 0.055 ± 0.004 0.043 ± 0.003 0.034
C22:0 0.278 ± 0.011 0.271 ± 0.008 0.680
C22:1n-9 2.355 ± 0.259 2.214 ± 0.213 0.694
C22:4n-6 0.238 ± 0.009 0.180 ± 0.008 0.001
C22:5n-6 0.118 ± 0.008 0.156 ± 0.026 0.127
C22:5n-3 0.377 ± 0.033 0.282 ± 0.022 0.038
C24:0 0.055 ± 0.004 0.128 ± 0.017 0.001
C22:6n-3 1.615 ± 0.085 1.518 ± 0.115 0.493
C24:1n-9 0.387 ± 0.017 0.283 ± 0.011 0.001
C26:0 0.244 ± 0.014 0.043 ± 0.006 0.001
ACL 17.972 ± 0.021 17.899 ± 0.018 0.019
SFA 29.808 ± 0.492 31.093 ± 0.416 0.069
UFA 70.192 ± 0.492 68.906 ± 0.416 0.069
MUFA 26.577 ± 0.507 26.163 ± 0.654 0.616
PUFA 43.615 ± 0.657 42.742 ± 0.789 0.401
PUFAn3 2.562 ± 0.100 2.303 ± 0.156 0.154
PUFAn6 41.053 ± 0.706 40.439 ± 0.851 0.582
DBI 137.867 ± 1.202 134.605 ± 1.151 0.068
PI 81.355 ± 1.275 78.730 ± 1.371 0.178
AI 49.801 ± 3.379 46.676 ± 2.755 0.504
Abbreviations: ACL, average chain length; SFA, saturated fatty acids; UFA, unsaturated fatty acids; MUFA, monounsaturated 
fatty acids; PUFA, polyunsaturated fatty acids; PUFAn-3, polyunsaturated fatty acids series n-3; PUFAn-6, polyunsaturated 
fatty acids series n-6; DBI, double bond index; PI, peroxidizability index; AI, anti-inflammatory index.
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2-site monoclonal non-isotopic system (Architect, Abbott 
Laboratories, Abbott Park, IL). Sex hormone binding 
globulin (SHBG), androstendione and testosterone were 
measured in our hospital’s Clinical Analysis Service using 
specialized chemiluminiscence techniques. 
Lipidomic analysis
Chemicals. Synthetic lipids were obtained from 
Avanti Polar Lipids Inc. (Alabaster, AL, USA) and 
Sigma-Aldrich (Madrid, Spain). Fatty acid methyl ester 
standards were obtained from Larodan Fine Chemicals 
(Mälmo, Sweden) and from Sigma-Aldrich (Madrid, 
Spain).  Methyl tert-butyl ether (MTBE) LC-MS, 
acetonitrile LC-MS, isopropanol LC-MS, potassium 
chloride, chloroform, ammonium formate and ammonium 
hydroxide were purchased from Sigma-Aldrich (Madrid, 
Spain); methanol was from Carlo Erba (Milano, Italy); 
acetone was from Riedel-de-Häen (Seelze, Germany); 
and LC/MS-grade isopropanol and formic acid were from 
Baker (Phillipsburg, NJ, USA).
Lipidomic analysis: plasma lipidome
Preparation of Lipid Standards. Lipid 
standards consisting of isotopically labeled lipids 
(see Supplementary Table 1) were used for external 
standardization (i.e. lipid family assignment) and internal 
standardization (i.e. for adjustment of potential inter- and 
intra-assay variances). Stock solutions were prepared by 
dissolving lipid standards in MTBE at a concentration of 
1 mg/mL and working solutions were diluted to 2.5 μg/
mL in MTBE.
Lipid extraction. Lipidomic analysis was based on 
a previously validated method [67]. Briefly, in order to 
precipitate plasma protein fraction, 5 μl of miliQ water 
and 20 μl of methanol were added to 10 μl of plasma 
sample. After the addition, samples were vigorously 
shaken for 2 min. Then, for lipid extraction, 250 μl 
of MTBE (containing internal lipid standards) were 
added and samples were immersed in a water bath 
(ATU Ultrasonidos, Valencia, Spain) with an ultrasound 
frequency and power of 40 kHz and 100 W, respectively, 
at 10°C for 30 min. Then, 75 μL of miliQ water were 
added to the mixture and organic phase was separated by 
centrifugation (1,400 g) at 10°C for 10 min. Lipid extracts, 
contained in the upper phase, were collected and subjected 
to mass-spectrometry. A pool of all lipid extracts was 
prepared and used as quality controls (QC) as previously 
described [68].
LC-MS/MS method. Lipid extracts were subjected 
to liquid chromatography coupled to mass-spectrometry 
(LC-MS) using an Agilent UPLC 1290 coupled to the 
Q-TOF MS/MS 6520 (Agilent Technologies, Barcelona, 
Spain) basing on previously published method [69]. 
Sample compartment was refrigerated at 4°C and, for each 
sample, 10 μl of lipid extract was applied onto 1.8 µm 
particle 100 × 2.1 mm id Waters Acquity HSS T3 column 
(Waters, Mildord, MA, USA) heated at 55°C. The flow 
rate was 400 μl/min with solvent A composed of 10mM 
ammonium acetate in acetonitrile-water (40:60, v/v) and 
solvent B composed of 10 mM ammonium acetate in 
acetonitrile-isopropanol (10:90, v/v). The gradient started 
at 40% B and reached 100% B in 10min and held for 
2 min. Finally, the system was switched back to 60% B and 
equilibrated for 3 min.  Duplicate runs of the samples were 
performed to collect positive and negative electrospray 
ionized lipid species in a TOF mode, operated in full-scan 
mode at 100 to 3000 m/z in an extended dynamic range 
(2 GHz), using N2 as nebulizer gas (5 L/min, 350°C). 
The capillary voltage was set 3500 V with a scan rate of 
1 scan/s. Continuous infusion using a double spray with 
masses 121.050873, 922.009798 (positive ion mode) and 
119.036320, 966.000725 (negative ion mode) was used for 
in-run calibration of the mass spectrometer. For MS/MS 
analyses we applied a previously described method [70].
Data Analyses. The MassHunter Data Analysis 
Software (Agilent Technologies, Barcelona, Spain) 
was used to collect the results and the MassHunter 
Qualitative Analysis Software (Agilent Technologies, 
Barcelona, Spain) to obtain the molecular features of 
the samples, representing different, co-migrating ionic 
species of a given molecular entity (i.e. ion adducts) 
using the Molecular Feature Extractor algorithm (Agilent 
Technologies, Barcelona, Spain) [71]. This algorithm is 
a compound-finding technique that locates individual 
sample components (molecular features), even when 
chromatograms are complex and compounds are not well 
resolved. MFE locates ions that are covariant (rise and fall 
together in abundance), but the analysis is not exclusively 
based on chromatographic peak information. The 
algorithm uses the accuracy of the mass measurements 
to group related ions, related by charge-state envelope, 
isotopic distribution, and/or the presence of adducts and 
dimers. It assigns multiple species (ions) that are related to 
the same neutral molecule (for example, ions representing 
multiple charge states or adducts of the same neutral 
molecule) to a single compound that is referred to as a 
feature. Using this approach, the MFE algorithm can locate 
multiple compounds within a single chromatographic 
peak. We selected samples with a minimum absolute 
abundance of 5000 counts and with a minimum of 2 ions. 
Multiple charge states were not considered. Compounds 
from different samples were aligned using a RT window 
of 0.1% ± 0.15 min and a mass window of 5.0 ppm ± 
2.0 mDa. Only common features (found in at least 50% 
of the samples of the same condition) were analyzed, 
correcting for individual bias and excluding possible 
contaminants and artefacts. Finally, the MassHunter Mass 
Profiler Professional Software (Agilent Technologies, 
Barcelona, Spain) was used to perform a non-targeted 
lipidomic analysis over the extracted features. Only 
common features (found in at least 50% of the samples 
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of the same condition) were taken into account to correct 
for individual bias.  Multivariate statistics (Hirerchical 
Clustering, PCA and PLS-DA analyses) were done 
using both MassHunter Mass Profiler Professional 
and Metaboanalyst softwares. Variable importance in 
projection (VIP) score was calculated using Metaboanalyst 
software [72, 73]. The masses representing significant 
differences by ANOVA (p < 0.05 with Benjamini-
Hochberg Multiple Testing Correction) were searched 
against the LIPID MAPS database (The LIPID MAPS 
Lipidomics Gateway, http://www.lipidmaps.org/, May 
2014) (exact mass ppm <20) and the MS/MS spectra were 
checked using the LipidBlast software [74].
Lipidomic analysis: plasma fatty acids
Fatty acid preparation. After lipid extraction, fatty 
acyl groups were analyzed as methyl esters derivatives by 
gas chromatography (GC) [70]. Briefly, fatty acids were 
transesterified by incubation in 2 ml of 5% methanolic HCl 
at 75°C for 90 min. The resulting fatty acid methyl esters 
(FAMEs) were extracted by adding 2 ml of n-pentane and 
1 ml of saturated NaCl solution. The n-pentane phase was 
separated, evaporated under N2 gas, re-dissolved in 80 μl 
of carbon disulfide and 2 μl were used for GC analysis. 
GC method. The analysis was performed on a GC 
System 7890A with a Series Injector 7683B and a flame 
ionization detector (FID) (Agilent Technologies Inc., 
Barcelona, Spain) equipped with a DBWAX capillary 
column (length 30 m × inner diameter 0.25 mm × film 
thickness 0.20 μm; Agilent Technologies Inc., Barcelona, 
Spain). The injections were performed in the splitless 
mode. The temperature of the injector was 220°C. The 
flow rate of helium (99.99%) carrier gas was maintained 
at a constant rate of 1.8 ml/min. The column temperature 
was held at 145°C for 5 min; subsequently, the column 
temperature was increased by 2°C/min to 245°C for 
50 min, and held at 245°C for 10 min, and with a post-run 
of 250°C for 10 min. 
Data analysis. Identification of the twenty-
four FAMEs was made by comparison with authentic 
standards. Results were expressed as mol%. The fatty 
acid profile detected, identified and quantified represents 
more than 95% of the total chromatogram. The following 
fatty acid indexes were calculated: saturated fatty acids 
(SFA); unsaturated fatty acids (UFA); monounsaturated 
fatty acids (MUFA); polyunsaturated fatty acids (PUFA) 
from n-3 and n-6 series (PUFAn-3 and PUFAn-6); average 
chain length (ACL) = [(Σ%Total14 × 14) + (Σ%Total16 × 
16) + (Σ%Total18 × 18) + (Σ%Total20 × 20) + (Σ%Total22 
× 22)+ (Σ%Total24 × 24)]/100]; double bond index (DBI) 
= [(1 × Σmol% monoenoic) + (2 × Σmol% dienoic) + (3 × 
Σmol% trienoic) + (4 × Σmol% tetraenoic) + (5 × Σmol% 
pentaenoic) + (6 × Σmol% hexaenoic)]; peroxidizability 
index (PI) = [(0.025 × Σmol% monoenoic) + (1 × Σmol% 
dienoic) + (2 × Σmol% trienoic) + (4 × Σmol% tetraenoic) 
+ (6 × Σmol% pentaenoic) + (8 × Σmol% hexaenoic)]; and 
anti-inflammatory index (AI): [[(20:3n-6) + (20:5n-3) + 
(22:6n-3)]/ (20:4n-6)]*100.
Statistics. Comparisons between groups were 
analyzed with one way ANOVA followed by DMS tests. 
These statistical analyses were performed using the SPSS 
software (SPSS, Chicago, IL, USA). The level of statistical 
significance was set at p < 0.05 in all the analyses.
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